Evidence map›Paper›PMID 25421310›Full record

ArticleThe Journal of pathology2015

Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase.

Jeroen T Buijs, Kasia M Matula, Henry Cheung, Marianna Kruithof-de Julio, Maaike H van der Mark, Thomas J Snoeks, Ron Cohen, Willem E Corver, Khalid S Mohammad, Jos Jonkers and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Mouse Models of Breast Cancer Bone Metastasis.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Jeroen T BuijsDepartment of Urology, Leiden University Medical Centre, Leiden, The Netherlands.
Kasia M Matula
Henry Cheung
Marianna Kruithof-de Julio
Maaike H van der Mark
Thomas J Snoeks
Ron Cohen
Willem E Corver
Khalid S Mohammad
Jos Jonkers
Theresa A Guise
Gabri van der Pluijm
Leiden University Medical Center · NLLeiden University · NLIndiana University – Purdue University Indianapolis · USThe Netherlands Cancer Institute · NL

Funding

Differential TGF-Beta Signaling in Bone Microenviroment: Impact on Tumor GrowthU01CA143057 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI BHOWMICK, NEIL A., GUISE, THERESA A · 2011 to 2015
$2.7M
NCI NIH HHS U01 CA143057
6 · The paper itself

Abstract

Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most frequently occurring histological subtypes of breast cancer, accounting for 80-90% and 10-15% of the total cases, respectively. At the time of diagnosis and surgical resection of the primary tumour, most patients do not have clinical signs of metastases, but bone micrometastases may already be present. Our aim was to develop a novel preclinical ILC model of spontaneous bone micrometastasis. We used murine invasive lobular breast carcinoma cells (KEP) that were generated by targeted deletion of E-cadherin and p53 in a conditional K14cre;Cdh1((F/F));Trp53((F/F)) mouse model of de novo mammary tumour formation. After surgical resection of the growing orthotopically implanted KEP cells, distant metastases were formed. In contrast to other orthotopic breast cancer models, KEP cells readily formed skeletal metastases with minimal lung involvement. Continuous treatment with SD-208 (60 mg/kg per day), an orally available TGFβ receptor I kinase inhibitor, increased the tumour growth at the primary site and increased the number of distant metastases. Furthermore, when SD-208 treatment was started after surgical resection of the orthotopic tumour, increased bone colonisation was also observed (versus vehicle). Both our in vitro and in vivo data show that SD-208 treatment reduced TGFβ signalling, inhibited apoptosis, and increased proliferation. In conclusion, we have demonstrated that orthotopic implantation of murine ILC cells represent a new breast cancer model of minimal residual disease in vivo, which comprises key steps of the metastatic cascade. The cancer cells are sensitive to the anti-tumour effects of TGFβ. Our in vivo model is ideally suited for functional studies and evaluation of new pharmacological intervention strategies that may target one or more steps along the metastatic cascade of events.

Indexed as

AnimalsApoptosisBone NeoplasmsBreast NeoplasmsCarcinoma, LobularCdh1 ProteinsCell Line, TumorCell ProliferationFemaleMammary Neoplasms, ExperimentalMice, KnockoutNeoplasm MicrometastasisProtein Kinase InhibitorsProtein Serine-Threonine KinasesPteridinesReceptors, Transforming Growth Factor betaCdh1 ProteinsFzr1 protein, mouseProtein Kinase InhibitorsProtein Serine-Threonine KinasesPteridinesReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type ISD-208Tumor Suppressor Protein p53breast cancerinvasive lobular carcinomametastasisminimal residual diseasemouse modelreceptor I kinase inhibitorSD-208TGFβ

Identifiers

PMID25421310
PMCPMC4407922
OpenAlexW2142495396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.